CDC Finalizes Advisory Panel Recommendations.

M2 PRESSWIRE-23 March 2007-Early Watch: CDC Finalizes Advisory Panel Recommendations(C)1994-2007 M2 COMMUNICATIONS LTD

RDATE:23032007

Merck & Co. (NYSE:MRK), Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com.

During early morning trading shares are up .5% to $44.35 with over 311,000 in volume. This comes as the U.S. Centers for Disease Control and Prevention (CDC) has adopted the unanimous recommendation of its Advisory Committee on Immunization Practices (ACIP) for the use of GARDASIL (Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine) in girls and women ages 11 through 26. GARDASIL is indicated to help prevent cervical cancer, precancerous and low-grade cervical lesions, vulvar and vaginal precancers and genital warts caused by human papillomavirus (HPV) types 6, 11, 16 and 18. The vaccination guidelines, published in the CDC's Morbidity and Mortality Weekly Report (MMWR), and now available to physicians, finalize the provisional recommendations issued by the ACIP in June 2006.

MarketGainer.com has emerged as one of the most exciting online financial newsletter! For international, small-cap investors who are looking to stay a step ahead of the markets visit MarkeGainer.com.

The guidelines state that routine vaccination with GARDASIL (referred…